Fig. 4From: Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patientsFive-year relapse-free survival (RFS) curves of patients treated with [I-OHP(+), indicated in red] and without oxaliplatin [I-OHP(−), indicated in blue] according to the 55-gene classifier (55GC) subtypes and primary tumor sidedness (top: left-side; bottom: right-side)Back to article page